NCT02292550 - Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 14, 2015

Primary Completion Date

September 26, 2018

Study Completion Date

September 26, 2018

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Ribociclib

CDK 4/6 inhibitor

DRUG

Ceritinib

ALK inhibitor

Trial Locations (8)

Novartis Investigative Site, Taipei

Novartis Investigative Site, Marseille

Novartis Investigative Site, Rozzano

Novartis Investigative Site, Bologna

Novartis Investigative Site, Tainan City

Novartis Investigative Site, Boston

Novartis Investigative Site, Seoul

Novartis Investigative Site, Barcelona